Teva Pharmaceutical Industries (TEVA) Tops Q3 EPS by 2c
Tweet
Share
E-mailGet Alerts TEVA Hot Sheet
Join SI Premium – FREE
Teva Pharmaceutical Industries (NASDAQ: TEVA) reported Q3 EPS of $1.25, $0.02 better than the analyst estimate of $1.23. Revenue for the quarter came in at $4.34 billion versus the consensus estimate of $4.54 billion.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Teva Announces Proposed Acquisition of a Novel Neuroscience Product Reinforcing Disciplined Business Development Approach Under Pivot to Growth Strategy
- Immuneering touts Phase 3 trial as FDA clears new pancreatic cancer drug
- Lucky Strike Entertainment Corporation (LUCK) reported Q2 Revenue ; Offers Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
